Review

Archives of Pharmacal Research

, Volume 21, Issue 2, pp 89-105

First online:

Current status of anti-HBV chemotherapy

  • Joon H. HongAffiliated withCenter for Drug Discovery, Pharmaceutical & Biomedical Sciences, College of Pharmacy, The University of Georgia
  • , Yongseok ChoiAffiliated withCenter for Drug Discovery, Pharmaceutical & Biomedical Sciences, College of Pharmacy, The University of Georgia
  • , Byoung K. ChunAffiliated withCenter for Drug Discovery, Pharmaceutical & Biomedical Sciences, College of Pharmacy, The University of Georgia
  • , Kyeong LeeAffiliated withCenter for Drug Discovery, Pharmaceutical & Biomedical Sciences, College of Pharmacy, The University of Georgia
  • , Chung K. ChuAffiliated withCenter for Drug Discovery, Pharmaceutical & Biomedical Sciences, College of Pharmacy, The University of Georgia

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

In the past decade, significant progress has been achieved in the battle against hepatitis B virus. In addition to the immunomodulating agents such as interferon-α and thymosin, many novel antiviral agents have been discovered, among which nucleoside analogues are the main-stay. New-generation compounds such as 3TC and famciclovir have shown promise in the treatment of patients chronically infected by this virus, and are on the line for approval. However, viral rebound after cessation of therapy still remains a major problem. Additionally, the reports on the drug resistance to these antiviral agents suggest that combination therapy will be the eventual strategy (Bartholomewet al., 1997; Tippleset al., 1996). Therefore, developments of safe and effective antiviral agents which do not cross-resist with currently available antiviral drugs are still much needed.

Key words

Hepatitis B virus Immunomodulationg agents Chemotherapy Nucleoside analogues 3TC Famciclovir Resistance